Child-Friendly Medminder To Improve Compliance, Safety

描述（由申请人提供）：儿科慢性疾病影响美国1370万儿童。治疗这一不断增长的人口的一个基石是自我管理，这体现了药物依从性，家庭和学校的支持，以及儿童友好的辅助设备-每一个都与改善患者的结果有关。 电子依从性监测为跟踪给药依从性提供了新的选择。学校在帮助学生进行药物管理方面发挥了更积极的作用，在上学期间消除了无线通信和电子保健技术的一些障碍。最近，随着个人数字助理（PDA）的出现，电子消息传递展示了具有即时通信能力的前景。 利用我们公司在两个成功的产品开发中使用的强大技术平台-SmokeSignals（r）和MedSignals TM品牌，我们将开发一个medminding系统，该系统可以安排最佳剂量，将使用情况传达给服务器，允许患者和授权的第三方访问使用历史，并提供紧急通知。我们将开发和制造一个原型，这是一个非常先进的，非侵入性的，儿童友好的系统，特别是对危重或慢性病儿童的功能。它的软袋容器将容纳各种药物形式，包括药丸，吸入剂，血糖仪和胰岛素。 这项拟议的研究测试的可行性，有效性和可用性作为一个儿童友好的商业medminder与先进的能力。一项为期8周的随机对照试验将包括108名患有严重糖尿病、癫痫或哮喘的儿童。我们假设，接受功能齐全的器械的治疗组将显示出与改善药物自我管理相关的几项益处。

DESCRIPTION (provided by applicant): Pediatric chronic illness impacts 13.7 million children in America. A cornerstone in the treatment of this growing population is self-management, which embodies medication compliance, family and school support, and child-friendly assistive devices -- each being associated with improved patient outcomes. Electronic compliance monitoring has provided new options for tracking dosing adherence. Schools are taking a more active role in aiding students with medication management, lifting some barriers to wireless communications and e-health technologies during the school day. Recently, with the advent of personal digit assistants (PDAs), electronic messaging is demonstrating promise with just-in-time communication capabilities. Leveraging our company's strong technological platforms that were used in two successful product developments -SmokeSignals(r) and MedSignals TM brands, we will develop a medminding system that schedules optimal dosings, communicates usage to servers, permits the patient and authorized third -parties access to usage history, and provides emergency notification. We will develop and fabricate a prototype that is a highly advanced, non-invasive, child-friendly system that is especially functional for critically or chronically ill children. Its soft pouch container will accommodate a variety of medicine forms, including pills, inhalants, glucometers, and insulin. This proposed study tests the feasibility, efficacy and usability as a child-friendly commercial medminder with advanced capabilities. A randomized, controlled 8-week trial will include 108 children with severe diagnoses of diabetes, epilepsy, or asthma. We hypothesize that the treatment group, receiving a fully functioning device, will show several benefits associated with improved self-management of medications.